OTIC Otonomy, Inc.

16.75
+0.15  (0.9%)
Previous Close 16.60
Open 16.60
Price To book 2.33
Market Cap 505.75M
Shares 30,194,000
Volume 123,250
Short Ratio 19.24
Av. Daily Volume 157,998

SEC filingsSee all SEC filings

  1. 8-K - Current report 17528441
  2. 8-K - Current report 162024080
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161971803
  4. 8-K - Current report 161971504
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161807344

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved December 11 2015
OTIPRIO (ciprofloxacin otic suspension)
Ear Tube Placement Surgery
Second Phase 3 trial initiated March 2016. Data from both Phase 3 trials due 2H 2017.
OTO-104 AVERTS-1 and AVERTS-2
Ménière’s disease
Phase 2 trial completed October 2016. End of Phase 2 meeting planned with FDA 1H 2017.
OTIPRIO
Pediatric patients with acute otitis media with tympanostomy tubes (AOMT)
Phase 2 trial initiated December 2016.
OTO-104
Pediatric patients undergoing cisplatin chemotherapy
Phase 3 trial met primary endpoint - January 5, 2017. sNDA filing to be submitted 1H 2017.
OTIPRIO
Acute otitis externa

Latest News

  1. OTONOMY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  2. Otonomy Provides Corporate and Product Pipeline Update
  3. Otonomy, Inc. breached its 50 day moving average in a Bullish Manner : OTIC-US : January 6, 2017
  4. Why These 5 Biopharma Stocks Are Making Massive Gains on Thursday
  5. Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis Externa
  6. Otonomy's ear infection drug succeeds in late-stage trial
  7. Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis Externa
  8. What We’re Watching In Biotech For January: Otonomy Inc (OTIC) And TESARO Inc (TSRO)
  9. Otonomy to Present at the J.P. Morgan Healthcare Conference
  10. Otonomy, Inc. – Value Analysis (NASDAQ:OTIC) : December 19, 2016
  11. Otonomy, Inc. breached its 50 day moving average in a Bearish Manner : OTIC-US : December 16, 2016
  12. Hedge Funds Are Selling Otonomy Inc (OTIC)
  13. ETFs with exposure to Otonomy, Inc. : December 2, 2016
  14. Otonomy, Inc. breached its 50 day moving average in a Bearish Manner : OTIC-US : December 1, 2016
  15. OTONOMY, INC. Files SEC form 8-K, Regulation FD Disclosure
  16. Otonomy Appoints Kathie M. Bishop, Ph.D., as Chief Scientific Officer
  17. Otonomy to Present at Piper Jaffray Healthcare Conference
  18. Edited Transcript of OTIC earnings conference call or presentation 3-Nov-16 8:30pm GMT
  19. OTONOMY, INC. Financials
  20. Otonomy Reports Third Quarter 2016 Financial Results and Provides Corporate Update

SEC Filings

  1. 8-K - Current report 17528441
  2. 8-K - Current report 162024080
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161971803
  4. 8-K - Current report 161971504
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161807344
  6. 8-K - Current report 161807296
  7. 8-K - Current report 161726854
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 161631701
  9. 8-K - Current report 161631608
  10. DEF 14A - Other definitive proxy statements 161600801